Cytosorbents Corp — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
CytoSorbents reported Q2 2026 revenue of $9.6M (flat YoY), with gross margin improving to 73% from 71% YoY. Operating loss improved 27% to $2.6M versus $3.6M in Q2 2025. Net loss was $4.4M ($0.07/share) due to foreign currency headwinds; adjusted net loss improved 22% to $2.8M ($0.05/share). Cash burn reduced to $0.4M in Q2 (excluding restructuring). Company reduced workforce ~23% since Sept 2025, targeting operating cash flow breakeven in H2 2026. Management outlined four value drivers: breakeven, CytoSorb growth, DrugSorb-ATR FDA approval (targeting early 2027 submission, $500M–$1B US market opportunity), and HemoDefend-BGA strategic options.
Why this rating
Operational improvements (margin, cash burn, cost cuts) are positive but offset by flat revenue and near-zero cash position ($5.9M on ~$61M market cap, ~10% of cap). Breakeven target credible but unmet. DrugSorb-ATR is high-value strategically but regulatory approval uncertain, years away. Modest near-term clinical data, not transformational yet.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.